OBJECTIVE: Inflammatory bowel diseases (IBD) are associated with significant morbidity and economic burden. The variable course of IBD creates a need for predictors of clinical outcomes and health resource utilization (HRU) to guide treatment decisions. We aimed to identify clinical, serological or genetic markers associated with inpatient resource utilization in patients with ulcerative colitis (UC) and Crohn's disease (CD).
INTRODUCTION
Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is an immune-mediated condition driven by chronic inflammation of the intestinal mucosa. It is characterized by a highly variable clinical course associated with periods of remission and severe relapses. Approximately 1.4 million people are currently affected by IBD in the USA. 1 In North America the prevalence of CD ranges from 26 to 199 cases per 100 000 individuals and that of UC ranges from 37 to 246 cases per 100 000 individuals. 1 Most commonly diagnosed in late adolescence and early adulthood, IBD is an incurable disease that frequently commits patients to lifelong medical care that often results in substantial medical expenses. In 2004 the mean annual cost of treatment was $8265 per patient for CD and $5066 per patient for UC in the USA. The total annual diseaseattributable direct cost of IBD in the USA is estimated to be $6.3 billion ($3.6 billion for CD and $2.7 billion for UC). 2 Most of the costs occur during the first year of diagnosis. [3] [4] [5] Surgery and hospitalizations were previously the primary drivers of cost but they have recently played a smaller role since the introduction of biologic agents. 2, 6 In 2014, anti-tumor necrosis factor (TNF) agents accounted for 64.1% of the health-care costs of CD and 31.4% of UC while hospitalizations and surgery accounted for 19% and <1%, respectively, for CD and 23.3% and 1.4%, respectively, for UC. 7 It is unclear from published data whether anti-TNF agent use in IBD is associated with overall increase or decrease in health-care expenditure when factoring the expense of therapy against the potential cost savings associated with reduced rates of hospitalizations and surgery. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] IBD has a profound economic burden that is likely to continue to grow. With ever-increasing pressures to reduce medical health-care expenses, identifying patients at risk of increased health-care resource utilization (HRU) is a potential strategy to reduce health-care expenditure and improve outcomes by developing individualized management strategies. HRU is a measure of the amount or cost of health services utilized. In patients with CD, younger age, fistulizing disease, use of biologics, disease activity, socioeconomic status, disease duration, gender and previous need for steroid therapy are all associated with increased HRU. 2, 19, 20 While in patients with UC, disease severity, use of biologics, C-reactive protein levels, age, gender and smoking are associated with increased HRU. 19, 21 Although many clinical predictors of increased HRU have been identified, genetic and serological predictors of HRU in IBD have not been well described or systematically investigated. One study has suggested that the NOD2/CARD15 mutation Gly908Arg and anti-Saccharomyces cerevisiae antibodies (ASCA) seropositivity are associated with a longer duration of surgical hospitalization and higher surgical hospitalization costs in patients with CD. 22 However, the study was limited to only patients with CD and analyzed only the presence of NOD2/CARD15 mutations and ASCA. Thus, we aimed to expand on these findings by identifying genetic or serological markers in addition to clinical factors associated with the utilization of hospital-based resources using a retrospective cohort design that included both patients with CD and with UC.
PATIENTS AND METHODS

Participants
We conducted a retrospective cohort study using participants from the Cedars-Sinai Medical Center MIR-IAD Research Repository (IRB no. 3358) who had at least one hospital admission or visit to an emergency department between 22 December 2011 and 31 December 2014. The Cedars-Sinai Medical Center IBD MIRIAD Research Repository contains clinical (demographics, disease phenotype, hospitalization history), serological and genetic data on 5756 patients with IBD who had given their consent prospectively followed at the Cedars-Sinai Medical Center IBD Center.
HRU: primary and secondary outcomes
Our primary inpatient HRU outcome measure was defined using the All Patient Refined Diagnosis Related Group (APR-DRG) classification system, which calculates national relative inpatient cost weights based on comorbidities, age, procedures and principal diagnoses. 23 We used the APR-DRG grouper 23 to identify the cost weight for each inpatient hospitalization and recorded the sum of all APR-DRG cost weights. Secondary outcomes included the patients' number of emergency department visits, hospital days, number of hospitalizations, number of medical admissions and number of surgical admissions. A surgical admission was defined as a hospitalization that required at least one operation, which included elective or urgent operations.
Clinical and serological phenotyping
Patients' data (age, gender, self-reported race, selfreported ethnicity and insurance coverage) were obtained from the medical center's data warehouse. Patients' insurance coverage was identified as dual eligible if they were insured by both Medicare and Medi-Cal (California's Medicaid program) at time of their first encounter with the system, and being dual P Gu et al.
Journal of Digestive Diseases 2018; 19; 15-23 eligible was used as a proxy for low socioeconomic status. 24 IBD-associated serologies (ASCA immunoglobulin G and immunoglobulin A), anti-nuclear cytoplasmic antibody (ANCA), anti-flagellin (antiCBir1), and anti-outer membrane porin C (antiOmpC) were measured with enzyme-linked immunosorbent assay separately for UC and CD and with UC and CD as a combined IBD cohort. 25 In addition to individual qualitative and quantitative serological correlations, quartile sums using ASCA, anti-CBir1 and anti-OmpC were also assessed.
Genotyping
Genotyping of IBD-susceptibility genes [26] [27] [28] was performed at the Cedars-Sinai Medical Center using Illumina Infinium ImmunoChip-v1 array (San Diego, CA, USA) as previously described. 26 Genotype determinations (allele calls) were made using GenomeStudio 2011.1 with Genotyping Module 1.9.4. A methodological review was performed for single nucleotide polymorphisms (SNPs; Illumina), and SNPs were evaluated using several SNP statistic parameters, including call frequency, cluster separation, replicate and heritability error rates, heterozygous excess, theta mean and deviation, and mean R intensity. Raw genotyping intensities were visually examined to ensure accurate allele-calling for reported SNPs. The average genotyping rate across all samples that passed genotyping quality control was 99.82%. Approximately 2% of samples were genotyped in replicate (with both inter-plate and intraplate replicates) and yielded >99.9% concordance for the genotypes called.
Ethical considerations
The study was approved by the Cedars-Sinai Medical Center Institutional Review Board (IRB no. 42132, no. 3358). All participants provided their written informed consent upon their enrollment into the MIRIAD registry.
Statistical analysis
Univariate analysis
The Wilcoxon test was used to evaluate differences between patients with CD and UC on primary and secondary HRU outcomes. A threshold of P ≤ 0.05 was considered statistically significant. Associations with patients' characteristics, clinical factors and serology were assessed using a linear regression model, with adjustment for age and gender when available. A permutation test for statistical significance was performed for all analyses to control for a skewed distribution of the outcome variables. Given the number of clinical and individual factors evaluated, a nominal threshold of P ≤ 0.01 was considered statistically significant.
Genetic analysis
The association between HRU and single nucleotide polymorphisms was evaluated with a linear regression model using PLINK, a whole genome association analysis tool set. 29, 30 A nominal level of significance of P ≤ 0.05 for the known IBD loci and P ≤ 1.0 × 10E-5 for the other SNPs in ImmunoChip was specified. Principle components from population stratification analysis were included to control for potential confounding, and a permutation test was performed in all analyses. 31 
Multivariate analysis
Patients' individual, clinical and serological factors associated with HRU were included in the multivariate analysis using linear regression. A permutation test was performed for all analyses to control for the impact of the skewed distribution of the outcome variables. P ≤ 0.01 in the joint model was considered statistically significant.
RESULTS
Clinical associations
A total of 858 patients met the inclusion criteria, including 562 patients with CD and 296 patients with UC. Women represented 50.6% of the patients. The median age was 41 years and the average disease duration was 13.5 years. Altogether 4.8% of patients had dual eligible status (Table 1) In patients with UC, current age had no significant association with HRU. In patients with CD, older current age was significantly associated with a higher HRU (P = 0. In patients with UC, dual eligible status was significantly associated with higher HRU (P = 0. Finally, in patients with UC, disease duration was not associated with HRU, but longer disease duration was associated with fewer surgical admissions (P = 0.043, ES: -0.014 [95% CI -0.021 to -0.007]). In CD and the IBD cohort overall, disease duration was not associated with HRU or any secondary outcomes.
Serological associations
In patients with UC, anti-CBir1 antibody seropositivity (P = 0.003, ES: 1.865 [CI 95% 0.710-3.020]) and quantitatively increased anti-Cbir1 antibody levels (P = 0.005, ES: 0.009 [CI 95% 0.020-0.052]) were significantly associated with higher HRU. Furthermore, anti-CBir1 antibody seropositivity (P = 0.009, ES: 7.538 [95% CI 2.000-13.076]) was associated with significantly more hospital days. In patients with CD, anti-CBir1 antibody seropositivity (P = 0.09), and quantitatively increased anti-CBir1 antibody (P = 0.02) were not significantly associated with HRU or any of the secondary outcomes. In the IBD cohort overall, anti-CBir1 antibody seropositivity (P = 0.010, ES: 0.574 [CI 95% 0.109-1.040]) and quantitatively increased anti-CBir1 antibody levels (P = 0.002, ES: 0.009 [CI 95% 0.003-0.014]) were significantly associated with higher HRU (Table 2) . Other IBD-associated serologies including antiOmpC antibody and p-ANCA were not associated with HRU or any of the secondary outcomes. Serological quartile sums were not associated with resource utilization. The seropositivity of rate of each serological marker is summarized in Table 2 .
Genetic associations
In total 525 patients were included in the genetic analysis. Several IBD-susceptibility loci met the predetermined nominal level of significance of association of P ≤ 5 × 10E-5 with HRU, including loci containing ICOSLG, BACH2, ORMDL3, BCMS, EDIL3 and HLA-B/HLA-C. Similarly, seven known IBD susceptibility SNPs met the nominal level of significance of association with HRU ( 
DISCUSSION
The current estimated annual cost of treating IBD is $6.3 billion in the USA and costs are rising despite advances in treatment. 2, 11, 13, 33 The ability to identify patients at risk of higher HRU could create an opportunity to reduce health-care expenditure by individualizing management strategies in order to reduce disease complications, hospitalizations and surgeries. We were able both to confirm a few known clinical associations with HRU and to describe novel serological and genetic associations with HRU.
Although several clinical features have previously been associated with higher HRU, data on predictive biomarkers is lacking. In a smaller cohort of patients with CD, the NOD2/CARD15 mutation Gly908Arg and ASCA seropositivity were associated with higher surgical hospitalization costs and longer surgical hospitalization duration, but we were unable to replicate these findings. 22 In a multivariable analysis, important factors predictive of HRU included anti-CBir1 antibody status, CD diagnosis and socioeconomic status. Furthermore, we identified several genes that met nominal levels of significance that are potentially predictive of HRU.
Anti-CBir1 antibody is a serological marker more commonly known to be associated with CD. 34, 35 Found on the Clostridium spp., CBir1 flagellin activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) through interactions with toll-like receptor 5 (TLR5) and, subsequently induces many proinflammatory cytokines. 36, 37 Anti-CBir1 antibody has been associated with more complicated and aggressive CD phenotypes, including small bowel, penetrating and fibrostenosing disease. 35, 38, 39 These patients often experience severe disease complications requiring multiple surgeries and expensive pharmacological therapies.
Even after controlling for CD status in the multivariable analysis, we found that anti-CBir1 antibody seropositivity was significantly associated with increased HRU. Anti-CBir1 antibody seropositivity was also associated with increased inpatient HRU in the UC cohort. This could suggest that UC patients with anti-CBir1 seropositivity may benefit from more aggressive therapy to reduce disease complications and financial burden. Additionally, anti-CBir1 antibody may have a prognostic role for HRU in patients with UC requiring ileal pouch anal anastomosis. Evidence has suggested that UC patients with preoperative anti-CBir1 antibody seropositivity have an increased incidence of pouchitis after ileal pouch anal anastomosis. 40 Additionally, anti-CBir1 antibody seropositivity may be an independent risk factor for developing CD-like pouchitis, which eventually requires expensive treatments with immunomodulators and biologics in 23-45% of the patients. [41] [42] [43] [44] In fact, one study has found that anti-CBir1 seropositivity is associated with infliximab use for pouchitis. 45 Thus, the existing data suggest that anti-CBir1 antibody may represent a population of patients both with UC and CD who are at risk for developing severe and complicated disease and may theoretically require more health-care resources to manage, such as hospitalizations, outpatient visits, surgeries and aggressive pharmacological therapy. Our study contributes to the literature by demonstrating that antiCBir1 antibody is associated with increased inpatient HRU in a large cohort of patients with IBD independent of diagnosis. While prospective studies are needed to confirm these findings, our results suggest that IBD patients with anti-CBir1 antibody seropositivity may benefit from more aggressive therapy and closer monitoring early in the disease course.
In addition to serological biomarkers, we found clinical factors associated with inpatient HRU. In the literature, CD is a well-established predictor of resource utilization and is associated with higher hospitalization costs, more hospitalizations and more bowel resections than UC. [11] [12] [13] Conversely, CD is associated with shorter hospital stays than UC. 11 In our cohort we confirmed that CD was associated with shorter hospital stays, but it was associated with lower overall inpatient HRU and fewer surgical admissions. There may be several explanations to reconcile this discrepancy. The observed differences may be a consequence of varying length of follow-up. We collected data within a 3-year period, and the higher number of surgical admissions observed in patients with UC may reflect the multiple operations required to complete an ileal pouch anal anastomosis. Thus, patients with CD may require more surgical interventions throughout their disease course, but patients with UC are more likely to require more surgeries within a short period of time immediately following the initial stage of their ileal pouch anal anastomoses. Also, while most studies included only IBD-related surgeries, we included all inpatient surgeries, such as extra-intestinal surgeries that may or may not be related to IBD. It is possible that patients with UC require more surgeries for extra-intestinal complications than those with CD. To our knowledge, this topic has not been well studied and may warrant further investigation in future studies. Finally, patients with UC had longer hospitalizations. This potentially resulted in higher inpatient HRU, which was likely to be surgery-related. Further studies are needed to confirm this and to identify major drivers of inpatient HRU in patients with UC versus those with CD.
Socioeconomic status, which is widely represented by dual eligible status in the literature, is also a well-described driver of HRU. 24 Socioeconomic status is associated with disparities in health service delivery for numerous chronic diseases, and low socioeconomic status is a well-described risk factor for poor health outcomes and higher HRU. 24, [46] [47] [48] In patients with IBD, low socioeconomic status is also associated with increased health-care costs including higher hospitalization rates, emergency department visits and inpatient mortality, 20, 49, 50 although low socioeconomic status has not been shown to influence surgery rates. [49] [50] [51] Similarly, we found that low socioeconomic status was associated with higher HRU, longer hospital stays, more hospitalizations and more emergency department visits. These findings may have several explanations. While lower socioeconomic status may theoretically be associated with disease severity or phenotype, one study of patients with CD did not find that association. 49 Medication adherence may play a role, but studies have not found a clear association between socioeconomic status and medication adherence in patients with IBD. 49, 52 Finally, our findings may indicate a shortcoming in outpatient health-care. Low-income patients have higher rates of potentially preventable hospitalizations. 53 Therefore, patients of lower socioeconomic status may lack access to the critical resources needed for a timely diagnosis and may experience delayed care that might have prevented disease complications. This could result in more frequent, and possibly preventable, hospitalizations, especially during an active flare, and eventually lead to surgery due to poorly controlled disease. Ultimately, patients of low socioeconomic status may represent a more vulnerable group in patients with IBD that requires more attention and support throughout their disease course. Further investigation is required to identify interventions that can help reduce disease complications and HRU in IBD patients with low socioeconomic status. Finally, we found several genes that met the nominal level of significance and that are potentially predictive of increased HRU. The clinical significance of these genes is summarized in Table 5 . Future studies with larger cohorts are needed to further clarify the role of genetic predictors of HRU in IBD.
Our study has several limitations, including its retrospective design. Furthermore, we were unable to control for IBD versus non-IBD related visits, different disease phenotypes within CD and UC, and known clinical features associated with increased HRU such as disease severity, smoking status and C-reactive protein levels. Future studies should control for these variables. Finally, our cohort included only patients who had had made at least one emergency department visit or had been hospitalized but it did not include patients who were well-maintained as outpatients. Thus, our findings may not be applicable to the general population with IBD and warrant careful interpretation. On the other hand, its strengths include a novel perspective in IBD management and a relatively large sample size for genetic and serological analyses. Our findings can form the basis of 
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• Involved in intestinal barrier function but its exact function remains unclear.
• Upregulated in colonic mucosa in patients with IBD. 55 • In vivo studies found PGTER4 −/− mice developed more severe dextran sulfate sodium-induced colitis than wild-type mice.
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NCF4
• Encodes a subunit of nicotinamide adenine dinucleotide phosphate (NAPDH) oxidase, which generates reactive oxygen species in response to bacterial infection.
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• Has been suggested to be associated with ileal-specific Crohn's disease. 58, 59 rs2457996 CXCL5
• Encodes expression of cytokine belonging to the CXC chemokine family.
• Increased expression in epithelial cells of intestinal mucosa of IBD patients with active inflammation compared with healthy controls.
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• Increased serum levels in patients having IBD with active disease compared with healthy controls. 61 rs6920220 TNFAIP3
• Ubiquitin-modifying enzyme that negatively regulates tumor necrosis factor and toll-like receptor responses and is induced by NF-κB activation.
• Probably involved in maintaining intestinal barrier integrity by supporting tight junction protein function.
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C1orf106
• Encodes for protein with unclear function. Recently named innate immune activator.
63
• Probably involved in MAPK and NF-κB activation, cytokine secretion, and intracellular bacterial clearance. rs7725339 IL12B
• Encodes for p40 subunit shared by interleukin 12 and 23.
• Required for the differentiation of Th17 cells, which mediate the host's defense and is involved in many autoimmune and inflammatory diseases.
rs7746082
PRDM1
• Encodes PR domain-containing 1, a zinc finger-containing transcriptional repressor involved in regulating terminal B and T cell differentiation.
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• Expressed predominantly in mucosal T cells and plasma cells.
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• Potentially involved in lymphocyte migration, T-cell expression and interferon-γ secretion.
EP4, prostaglandin E receptor 4; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; Th17, T helper 17.
future studies to establish the predictive value of anti-CBir1 antibody status and genetics for HRU in patients with IBD.
In conclusion, we have demonstrated that anti-CBir1 antibody seropositivity and low socioeconomic status are independently associated with higher inpatient HRU in a cohort of patients with IBD who required at least one emergency department visit or hospitalization, while CD diagnosis is independently associated with lower inpatient HRU. These findings suggest that anti-CBir1 antibody may play an important role in UC in addition to its known role in CD. Our findings also suggest that anti-CBir1 antibody seropositivity may be useful for identifying patients at risk of increased HRU. If this work is verified by future studies, clinicians may consider screening for anti-CBir1 antibody for prognostic information as well as informing their management strategies early in the disease course to reduce the financial burden on these patients.
